ABSTRACT
Objective:
To evaluate the
clinical effectiveness and
safety of Jiuwei-Zhuhuang San plus amoxilcillin
sodium and
sulbactam sodium in the
treatment of
bacterial pneumonia in
children.
Methods:
A total of 120
patients with
bacterial pneumonia in
children from 1 year to 14 years old were randomly divided into the study group ( n=90) and the
control group ( n=30) with ratio 3 to 1, the random sequence created by SAS
software. Both groups were treated with amoxilcillin
sodium for basic
treatment, the
observation group was treated with Jiuwei-Zhuhuang San. Both groups were treated for 1 week and followed up for 1 week. The
cough frequency, clinical effective rate,
symptoms and signs score, Traditonal
Chinese medicine (TCM) pattern scores and
adverse event rate were observed.
Results:
Eighteen cases were dropped and eliminated in the
observation group, and 4 cases were dropped and eliminated in the
control group, so 72 of
observation group and 26 of
control group were analyzed.
After treatment, the clinical effective rate of the
observation group was 27.8% (20/72), and the
control group was 0% (0/26), where the difference was significant ( χ2=7.445, P=0.006). The difference of TCM
syndrome score before and
after treatment in the
observation group (-16.8 ± 8.2 vs. -11.0 ± 5.8, t=-3.858) was lower than that of the
control group ( P<0.01). There was significant difference between the two groups ( Z=-2.347, P= 0.019) in the TCM
syndrome. The
cough frequency of the
observation group was 41.7% (30/72), and the
control group was 26.9% (7/26). There wasn’t any significant differences in the
cough frequency between two groups ( P>0.05). There was no statistical difference in
symptoms and signs score or
adverse event rate between two groups ( P>0.05).
Conclusion:
On the basis of
amoxicillin sodium and
sulbactam sodium, combined use of Jiuwei-Zhuhuang San can improve the
clinical effectiveness of
children with
bacterial pneumonia.